Clinical trial
A Phase II, Open-label Study of Polatuzumab-vedotin (PV) in Combination With Bendamustine and Rituximab for Patients With Mantle Cell Lymphoma, Who Relapse After Previous Therapy With Bruton Tyrosine Kinase Inhibitor
NCT04913103 is registered in ClinicalTrials.gov with Czech Lymphoma Study Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open-label Study of Polatuzumab-vedotin (PV) in Combination With Bendamustine and Rituximab for Patients With Mantle Cell Lymphoma, Who Relapse After Previous Therapy With Bruton Tyrosine Kinase Inhibitor
- Lead sponsor
- Czech Lymphoma Study Group
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 1, 2021
- Completion date
- August 31, 2027
- Enrollment
- 21 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.